Skip Navigation

Profile

Konstantinos Votanopoulos, M.D.Wake Forest Baptist Health

Doctor Rating

4.7 out of 5

131 Ratings
14 Comments
 

Konstantinos Votanopoulos, M.D.

Associate Professor, Surgical Sciences-Oncology

Clinical Interests

Sarcoma, Hepatobiliary Surgery, Gastrointestinal Oncology Surgery, Intra-Peritoneal Hyperthermic Chemotherapy, Pancreatic Surgery, Melanoma, Breast Cancer

Contact Information

Returning Patient Appointments: 336-716-4276
Department: 336-716-0545

Email: kvotanop@wakehealth.edu

Insurance Accepted »

Additional Languages

Greek

Education & Training

  • M.D., Aristoltle University School of Medicine, 1996
  • Residency, Surgery, University of Athens, 2002
  • Residency, Surgery, Baylor College of Medicine, 2007
  • Fellowship, Surgical Oncology, Roswell Park Cancer Inst, 2009

Board Certifications

  • American Board of Surgery, Surgery

Memberships

  • Michael E DeBakey Intl Sur Soc
  • Soc Of Surgical Oncology
  • Soc Of University Surgeons
  • Southern Surgical Assn
  • Am Coll Of Surgeons
  • Am Medical Assn
  • Am Soc of Clinical Oncology
  • Am Soc of Perit Surface Malign
  • Assn Of Academic Surgery
  • Hellenic Soc of Cancer Res
  • Hellenic Surgical Society

NPI Number

  • 1023212974
Konstantinos Votanopoulos, M.D.

Doctor Rating

4.7 out of 5

131 Ratings
14 Comments
 

Konstantinos Votanopoulos, M.D.

Associate Professor, Surgical Sciences-Oncology
Office of Women in Medicine and Science

Research Interests

Hyperthermia, Induced; Peritoneal Neoplasms; Chemotherapy, Cancer, Regional Perfusion; Stomach Neoplasms; Antineoplastic Combined Chemotherapy Protocols
More »

Contact Information

Academic: 336-716-0545 | Department: 336-716-0545

Email: kvotanop@wakehealth.edu

Recent Publications

A novel T-stage classification system for adrenocortical carcinoma: proposal from the US Adrenocortical Carcinoma Study Group. Poorman CE, Ethun CG, Postlewait LM, Tran TB, Prescott JD, Pawlik TM, Wang TS, Glenn J, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem A, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N, Solorzano CC,.. Ann Surg Oncol. 2018;25(2):520-527.

Is cytoreductive surgery with hyperthermic intraperitoneal chemotherapy justified for biphasic variants of peritoneal mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International registry. Votanopoulos KI, Sugarbaker P, Deraco M, Morris D, Glehen O, Elias D, De Simone M, Robella M, Heyd B, Kusamura S, Baratti D, Chouliaras K, Russell G, Shen P, Levine EA.. Ann Surg Oncol. 2018;25(3):667-673.

A multicenter randomized trial to evaluate hematologic toxicities after hyperthermic intraperitoneal chemotherapy with oxaliplatin or mitomycin in patients with appendiceal tumors. Levine EA, Votanopoulos KI, Shen P, Russell G, Fenstermaker J, Mansfield P, Bartlett D, Stewart JH.. J Am Coll Surg. 2018;226(4):434-443.

PCI is not predictive of survival after complete CRS/HIPEC in peritoneal dissemination from high-grade appendiceal primaries. Votanopoulos KI, Bartlett D, Moran B, Haroon CM, Russell G, Pingpank JF, Ramalingam L, Kandiah C, Chouliaras K, Shen P, Levine EA.. Ann Surg Oncol. 2018;25(3):674-678.

In vitro patient-derived 3D mesothelioma tumor organoids facilitate patient-centric therapeutic screening. Mazzocchi AR, Rajan SAP, Votanopoulos KI, Hall AR, Skardal A.. Sci Rep. 2018;8(1):2886.

Techniques for cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Dodson RM, Kuncewitch M, Votanopoulos KI, Shen P, Levine EA.. Ann Surg Oncol. 2018;():.

The effect of regional anesthesia on oncologic outcomes after resection of colorectal hepatic metastases. Garland M, Addis D, Russell G, Clark C, Levine E, Howerton R, Votanopoulos K, Dobson S, Shen P.. Am Surg. 2018;84(1):E29-E32.

Accuracy of the ACS NSQIP online risk calculator depends on how you look at it: results from the United States Gastric Cancer Collaborative. Beal EW, Saunders ND, Kearney JF, Lyon E, Wei L, Squires MH, Jin LX, Worhunsky DJ, Votanopoulos KI, Ejaz A, Poultsides G, Fields RC, Swords D, Acher AW, Weber SM, Maithel SK, Pawlik T, Schmidt CR.. Am Surg. 2018;84(3):358-364.

Quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma [abstract]. Ali Y, Sweeney J, Perry KC, Votanopoulos K, Shen P, Levine EA.. Ann Surg Oncol. 2018;25(Suppl 1):S142.

Evaluation of chest radiographs in workup for low-risk melanomas [abstract]. Brooks WC, Votanopoulos K, Shen P, Levine EA.. Ann Surg Oncol. 2018;25(Suppl 1):S183.

Curative surgical resection of adrenocortical carcinoma: determining long-term outcome based on conditional disease-free probability. Kim Y, Margonis GA, Prescott JD, Tran TB, Postlewait LM, Maithel SK, Wang TS, Glenn JA, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem A, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N,.. Ann Surg. 2017;265(1):197-204.

Minimally invasive resection of adrenocortical carcinoma: a multi-institutional study of 201 patients. Lee CW, Salem AI, Schneider DF, Leverson GE, Tran TB, Poultsides GA, Postlewait LM, Maithel SK, Wang TS, Hatzaras I, Shenoy R, Phay JE, Shirley L, Fields RC, Jin LX, Pawlik TM, Prescott JD, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY,.. J Gastrointest Surg. 2017;21(2):352-362.

Prognostic factors and significance of gastrointestinal leak after cytoreductive surgery (CRS) with heated intraperitoneal chemotherapy (HIPEC). Chouliaras K, Levine EA, Fino N, Shen P, Votanopoulos KI.. Ann Surg Oncol. 2017;24(4):890-897.

A multi-institutional study comparing the use of the American Joint Committee on Cancer 7th edition esophageal versus gastric staging system for gastroesophageal junction cancer in a western population. Adeshuko FA, Squires MH, Poultsides G, Pawlik TM, Weber SM, Schmidt C, Votanopoulos K, Fields RC, Maithel SK, Cardona K.. Am Surg. 2017;83(1):82-89.

Impact of lymph node ratio in selecting patients with resected gastric cancer for adjuvant therapy. Kim Y, Squires MH, Poultsides GA, Fields RC, Weber SM, Votanopoulos KI, Kooby DA, Worhunsky DJ, Jin LX, Hawkins WG, Acher AW, Cho CS, Saunders N, Levine EA, Schmidt CR, Maithel SK, Pawlik TM.. Surgery. 2017;162(2):285-294.

Interval between cytoreductions as a marker of tumor biology in selecting patients for repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Konstantinidis IT, Levine EA, Chouliaras K, Russell G, Shen P, Votanopoulos KI.. J Surg Oncol. 2017;116(6):741-745.

Blood transfusion and survival for resected adrenocortical carcinoma: a study from the United States Adrenocortical Carcinoma Group. Poorman CE, Postlewait LM, Ethun CG, Tran TB, Prescott JD, Pawlik TM, Wang TS, Glenn J, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem A, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N, Solorzano CC,.. Am Surg. 2017;83(7):761-768.

Predictors and prognostic implications of perioperative chemotherapy completion in gastric cancer. Karagkounis G, Squires MH III, Melis M, Poultsides GA, Worhunsky D, Jin LX, Fields RC, Spolverato G, Pawlik TM, Votanopoulos KI, Levine EA, Schmidt C, Bloomston M, Cho CS, Weber S, Masi A, Berman R, Pachter HL, Staley CA, Newman E, Maithel SK, Hatzaras I.. J Gastrointest Surg. 2017;21(12):1984-1992.

Frailty correlates with postoperative mortality and major morbidity after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Konstantinidis IT, Chouliaras K, Levine EA, Lee B, Votanopoulos KI.. Ann Surg Oncol. 2017;24(13):3825-3830.

Expert commentary on appendiceal neoplasms. Votanopoulos KI.. Dis Colon Rectum. 2017;60(12):1239-1240.

Outcomes of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients older than 70 years; survival benefit at considerable morbidity and mortality [reply to letter]. Votanopoulos KI, Shen P, Stewart JH, Levine EA, Russell G.. Ann Surg Oncol. 2017;24(Suppl 3):602.

A tumor-on-a-chip platform for screening precision driven medicines [abstract]. Forsythe S, Mehta N, Devarasetty M, Mazzochi A, Votanopoulos K, Gmeiner W, Skardal A.. Tissue Eng Part A. 2017;23(Suppl 1):S23.

Primary patient mesothelioma organoids for genetic mutation-driven experimental 3-deazaneplanocin a treatment [abstract]. Mazzocchi A, Rajan S, Votanopoulos K, Hall A, Skardal A.. Tissue Eng Part A. 2017;23(Suppl 1):S27.

Primary patient tumor organoids for personalized drug treatment [abstract]. Mazzocchi A, Votanopoulos K, Soker S, Skardal A.. Tissue Eng Part A. 2017;23(Suppl 1):S81.

Is the combination of distal pancreatectomy and cytoreductive surgery with HIPEC reasonable? Results of an International Multicenter study. Schwarz L, Votanopoulos K, Morris D, Yonemura Y, Deraco M, Piso P, Moran B, Levine EA, Tuech JJ.. Ann Surg. 2016;263(2):369-375.

Stoma creation and reversal after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Doud AN, Levine EA, Fino NF, Stewart JH, Shen P, Votanopoulos KI.. Ann Surg Oncol. 2016;23(2):503-510.

Conditional survival after cytoreductive surgery with heated intraperitoneal chemotherapy for low- and high-grade appendiceal primaries. Mogal HD, Levine EA, Russell G, Shen P, Stewart JH, Votanopoulos KI.. Ann Surg Oncol. 2016;23(2):534-538.

To Roux or not to Roux: a comparison between Roux-en-Y and Billroth II reconstruction following partial gastrectomy for gastric cancer. Tran TB, Worhunsky DJ, Squires MH, Jin LX, Spolverato G, Votanopoulos KI, Cho CS, Weber SM, Schmidt C, Levine EA, Bloomston M, Fields RC, Pawlik TM, Maithel SK, Norton JA, Poultsides GA.. Gastric Cancer. 2016;19(3):994-1001.

Is linitis plastica a contraindication for surgical resection: a multi-institution study of the U.S. Gastric Cancer Collaborative. Blackham AU, Swords DS, Levine EA, Fino NF, Squires MH, Poultsides G, Fields RC, Bloomston M, Weber SM, Pawlik TM, Jin LX, Spolverato G, Schmidt C, Worhunsky D, Cho CS, Maithel SK, Votanopoulos KI.. Ann Surg Oncol. 2016;23(4):1203-1211.

Nomograms to predict recurrence-free and overall survival after curative resection of adrenocortical carcinoma. Kim Y, Margonis GA, Prescott JD, Tran TB, Postlewait LM, Maithel SK, Wang TS, Evans DB, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem AI, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N,.. JAMA Surg. 2016;151(4):365-373.

Incidence of perioperative complications following resection of adrenocortical carcinoma and its association with long-term survival. Margonis GA, Amini N, Kim Y, Tran TB, Postlewait LM, Maithel SK, Wang TS, Evans DB, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Moses LE, Weber SM, Salem A, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N, Solorzano CC,.. World J Surg. 2016;40(3):706-714.

Routine admission to intensive care unit after cytoreductive surgery and heated intraperitoneal chemotherapy: not always a requirement. Mogal HD, Levine EA, Fino NF, Obiora C, Shen P, Stewart JH, Votanopoulos KI.. Ann Surg Oncol. 2016;23(5):1486-1495.

Adrenocortical carcinoma: impact of surgical margin status on long-term outcomes. Margonis GA, Kim Y, Prescott JD, Tran TB, Postlewait LM, Maithel SK, Wang TS, Evans DB, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem A, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N, Solorzano CC,.. Ann Surg Oncol. 2016;23(1):134-141.

Outcomes after resection of cortisol-secreting adrenocortical carcinoma. Margonis GA, Kim Y, Tran TB, Postlewait LM, Maithel SK, Wang TS, Glenn JA, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem A, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N, Solorzano CC, Kiernan CM,.. Am J Surg. 2016;211(6):1106-1113.

Outcomes of adjuvant mitotane after resection of adrenocortical carcinoma: a 13-institution study by the US Adrenocortical Carcinoma Group. Postlewait LM, Ethun CG, Tran TB, Prescott JD, Pawlik TM, Wang TS, Glenn J, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem A, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N, Solorzano CC, Kiernan CM,.. J Am Coll Surg. 2016;222(4):480-490.

Curative resection of adrenocortical carcinoma: rates and patterns of postoperative recurrence. Amini N, Margonis GA, Kim Y, Tran TB, Postlewait LM, Maithel SK, Wang TS, Evans DB, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem A, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N, Solorzano CC,.. Ann Surg Oncol. 2016;23(1):126-133.

Significance of intravenous thrombus in the management of adrenocortical carcinoma: prognosis and surgical implications [abstract]. Ahmed S, Tran T, Levine EA, Weber S, Salem AI, Postlewait LM, Maithel SK, Wang T, Hatzaras I, Shenoy R, Phay J, Shirley L, Fields RC, Jin L, Pawlik TM, Prescott J, Sicklick J, Gad S, Yopp A, Mansour J, Duh Q, Seiser N, Solorzano CC, Kiernan CM,.. Ann Surg Oncol. 2016;23(Suppl 1):S101.

Multi-institution review of the role of cytoreductive surgery and heated intraperitoneal chemotherapy in metastatic gastric adenocarcinoma in the U.S. [abstract]. Enomoto LM, Choudry MA, Pakrafter S, Magge D, Votanopoulos K, Levine EA, Turaga K, Pameijer C, Wong J.. Ann Surg Oncol. 2016;23(Suppl 1):S22.

Lymphadenectomy for adrenocortical carcinoma: is there a therapeutic benefit? [abstract]. Gerry J, Postlewait LM, Maithel S, Prescott J, Wang T, Glenn JA, Phay J, Keplinger K, Fields RC, Jin L, Weber S, Salem AI, Sicklick J, Gad S, Yopp A, Mansour J, Duh Q, Seiser N, Solorzano CC, Kiernan CM, Votanopoulos K, Levine EA, Hatzaras I, Shenoy R.. Ann Surg Oncol. 2016;23(Suppl 1):S100.

Adjuvant radiation therapy in patients undergoing curative intent resection for adrenocortical carcinoma: a multi-institutional experience [abstract]. Hatzaras I, Rao R, Tran TB, Postlewait LM, Maithel SK, Prescott J, Pawlik TM, Wang T, Phay J, Fields RC, Jin L, Weber S, Salem AI, Sicklick J, Gad S, Yopp A, Mansour J, Duh Q, Seiser N, Solorzano CC, Kiernan CM, Votanopoulos K, Levine EA, Newman E,.. Ann Surg Oncol. 2016;23(Suppl 1):S99.

Stage-specific prognostic effect of race in patients with resectable gastric adenocarcinoma: an 8-institution study of the US Gastric Cancer Collaborative. Wang A, Squires MH III, Melis M, Poultsides GA, Norton JA, Jin LX, Fields RC, Spolverato G, Pawlik TM, Votanopoulos KI, Levine EA, Schmidt C, Bloomston M, Cho CS, Weber S, Berman R, Pachter HL, Newman E, Staley CA, Maithel SK, Hatzaras I.. J Am Coll Surg. 2016;222(4):633-643.

Association of survival, postoperative morbidity and mortality following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy using quality of life assessments [abstract]. Dodson RM, Mogal H, Russell G, Duckworth KE, Votanopoulos K, Shen P, Levine EA, McQuellon RP.. Ann Surg Oncol. 2016;23(Suppl 1):S35.

Prognostic molecular subtypes of low-grade cancer of the appendix. Levine EA, Votanopoulos KI, Qasem SA, Philip J, Cummins KA, Chou JW, Ruiz J, D'Agostino R, Shen P, Miller LD.. J Am Coll Surg. 2016;222(4):493-503.

Repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: review of indications and outcomes. Mogal H, Chouliaras K, Levine EA, Shen P, Votanopoulos KI.. J Gastrointest Oncol. 2016;7(1):129-142.

Preoperative helicobacter pylori infection is associated with increased survival after resection of gastric adenocarcinoma. Postlewait LM, Squires MH III, Kooby DA, Poultsides GA, Weber SM, Bloomston M, Fields RC, Pawlik TM, Votanopoulos KI, Schmidt CR, Ejaz A, Acher AW, Worhunsky DJ, Saunders N, Swords D, Jin LX, Cho CS, Winslow ER, Cardona K, Staley CA, Maithel SK.. Ann Surg Oncol. 2016;23(4):1225-1233.

Optimal extent of lymphadenectomy for gastric adenocarcinoma: A 7-institution study of the U.S. Gastric Cancer Collaborative. Randle RW, Swords DS, Levine EA, Fino NF, Squires MH, Poultsides G, Fields RC, Bloomston M, Weber SM, Pawlik TM, Jin LX, Spolverato G, Schmidt C, Worhunsky D, Cho CS, Maithel SK, Votanopoulos KI.. J Surg Oncol. 2016;113(7):750-755.

Peritoneal dissemination from high-grade appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Cummins KA, Russell GB, Votanopoulos KI, Shen P, Stewart JH, Levine EA.. J Gastrointest Oncol. 2016;7(1):3-9.

Interaction of postoperative morbidity and receipt of adjuvant therapy on long-term survival after resection for gastric adenocarcinoma: results from the U.S. Gastric Cancer Collaborative. Jin LX, Sanford DE, Squires MH III, Moses LE, Yan Y, Poultsides GA, Votanopoulos KI, Weber SM, Bloomston M, Pawlik TM, Hawkins WG, Linehan DC, Schmidt C, Worhunsky DJ, Acher AW, Cardona K, Cho CS, Kooby DA, Levine EA, Winslow E, Saunders N,.. Ann Surg Oncol. 2016;23(8):2398-2408.

Readmission following gastric cancer resection: risk factors and survival. Acher AW, Squires MH, Fields RC, Poultsides GA, Schmidt C, Votanopoulos KI, Pawlik TM, Jin LX, Ejaz A, Kooby DA, Bloomston M, Worhunsky D, Levine EA, Saunders N, Winslow E, Cho CS, Leverson G, Maithel SK, Weber SM.. J Gastrointest Surg. 2016;20(7):1284-1294.

A histomorphologic grading system that predicts overall survival in diffuse malignant peritoneal mesothelioma with epithelioid subtype. Valente K, Blackham AU, Levine E, Russell G, Votanopoulos KI, Stewart JH, Shen P, Geisinger KR, Sirintrapun SJ.. Am J Surg Pathol. 2016;40(9):1243-1248.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Associate Professor, Surgical Sciences-Oncology

Clinical Interests

Sarcoma, Hepatobiliary Surgery, Gastrointestinal Oncology Surgery, Intra-Peritoneal Hyperthermic Chemotherapy, Pancreatic Surgery, Melanoma, Breast Cancer
Konstantinos Votanopoulos, M.D.

Konstantinos Votanopoulos, M.D.

Associate Professor, Surgical Sciences-Oncology
Office of Women in Medicine and Science

Doctor Rating

4.7 out of 5

Konstantinos Votanopoulos, M.D.131 Ratings
14 Comments


 

Doctor Ratings

The overall Patient Rating score is the average of responses to the nine questions listed below. The questions are from the Press Ganey Patient Satisfaction Survey. Responses are measured on a 1 to 5 scale, where 1 represents "very poor" and 5 represents "very good."
Press Ganey Patient Satisfaction Survey

CP concern for questions/worries
4.8
CP efforts to include in decisions
4.8
CP explanations of prob/condition
4.8
CP spoke using clear language
4.7
Friendliness/courtesy of CP
4.8
Likelihood of recommending CP
4.8
Patients' confidence in CP
4.8
Time CP spent with patient
4.7
Wait time at clinic
4.5



Patient Comments

Comments are taken from the Care Provider section of the Press Ganey Patient Satisfaction Survey. Comments are posted exactly as they are written. Comments are added weekly. To protect patient privacy and confidentiality, patient names are not included.

3/30/2018

Let's put it this way - I have a 12 hour drive (one way) to see dr. *Dr. Votanopoulos. This was my 4th post-op visit. This time *Dr. V. gave option of me to continue my monitoring in my home city - (but wants CT/CEA forwarded to him.) I chose to continue my check ups w/*Dr. V./ he is very detailed oriented (which I, as a retired _____ inestigator appreciates, explains things thoroughly, and listens to my worries (unlike most drs.) and truly cares.

3/23/2018

Outstanding care.

2/19/2018

Dr. V is the man.

2/8/2018

Very professional group

1/18/2018

Doctor V has the bed side manner of an angel. Even with cancer he made you feel safe. He was knowledgeable and very compassionate.

1/12/2018

I feel like Dr. V will take very good care of me. My life is very much in his hands.

12/28/2017

As always, I wish that the physicians had more time to spend with patients, but I understand how busy they are. Dr. V is WONDERFUL. He makes me feel that he REALLY cares about me.

12/19/2017

Very good stay @ hospital - everyone was great.

10/26/2017

He is the BEST

9/28/2017

Dr. V is an awesome doctor. He's very easy to talk to and he treats me great. He uses words that I can understand. He's just a great person overall.

8/28/2017

I'm very confident in *Dr. Votanopoulos and glad he is my dr. at Winslow.

8/25/2017

Dr. V is not only and excellent physician, he is a caring person. My family knows and trusts him as do I.

6/27/2017

Very thoughtful and explained options/tx plans uses a very practical minded approach - conservative minded.

6/21/2017

*Dr. V. has always provided great care for me. I have been granted an extension of my life through his care.

Quick Reference

Request an Appointment
New Patients

336-716-WAKE
888-716-WAKE

Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
Wake Forest Baptist Ranked among Nation’s ‘Best Hospitals’  25 Years in a Row by U.S. News & World ReportComprehensive Cancer Centers National Designation is Renewed2017-2018 Best DoctorsNursing Magnet StatusJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.

© Wake Forest Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC 27157. All Rights Reserved.